Your search history is turned on.
Date: February 29, 2024 Jurisdictions: Alberta, British Columbia
Hillestad.CFO Certification (December 31, 2023 - Q1) (W0451462-2).DOCX Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Christy Justice, Chief Financial Officer, of Hillestad Pharmaceuticals Inc. certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together...
Hillestad.CEO Certification (December 31, 2023 - Q1) (W0451461-2).DOCX Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Dan Hillestad, Chief Executive Officer, of Hillestad Pharmaceuticals Inc. certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together t...
Hillestad.Interim MD&A (December 31, 2023 - Q1) (W0451469).DOC Management Discussion and Analysis of Financial Condition and Results of Operations For the fiscal Quarter ended December 31, 2023 Date and Subject of Report This management discussion and analysis (MD&A) has been prepared effective February ...
Hillestad.Interim Financial Statements (December 31, 2023 - Q1) (W0451467).DOC Hillestad Pharmaceuticals, Inc. Condensed Consolidated Interim Financial Statements The period ended December 31, 2023 (Expressed in U.S. dollars) ...
Date: January 29, 2024 Jurisdictions: Alberta, British Columbia
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Christy Justice, Chief Financial Officer of Hillestad Pharmaceuticals Inc. certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorpora...
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Dan Hillestad, Chief Executive Officer of Hillestad Pharmaceuticals Inc. certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporate...
Hillestad.Annual MD&A (September 30, 2023 - YE) (W0450770).DOC Management Discussion and Analysis of Financial Condition and Results of Operations For the fiscal year ended September 30, 2023 This Management's Discussion and Analysis ("MD&A") has been prepared as of January 29, 2024 and should be read in conjun...
Date: January 29, 2024 Jurisdictions: Alberta
Create participation fee form FORM 13-501F2 CLASS 2 REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, HILLESTAD, Dan, an officer of the reporting issuer noted below have examined this Form 13-501F2 ( the Form) being submitted hereunder to the Alberta Securities Commission and certify that to my knowl edge, having exercised reasonable diligence, the ...
Microsoft Word - Hillestad 2023 Financial Statement Final Hillestad Pharmaceuticals, Inc. Consolidated Financial Statements September 30, 2023 and 2022 (Expressed in U.S. dollars) Page Independent auditors report 1 - 2 CONSOLIDATED FINANCIAL STATEMENTS Cons...
Date: September 1, 2023 Jurisdictions: Alberta, British Columbia
Hillestad.CEO Certification (June 30, 2023 - Q3) (W0446686-2).DOCX Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Dan Hillestad, Chief Executive Officer, of Hillestad Pharmaceuticals Inc. certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together the ...